Ipamorelin vs Sermorelin: What the Research Actually Compares
A comparison of ipamorelin and sermorelin based on published research: what each compound is, what studies measured, where evidence is stronger, and what remains unknown.
Ipamorelin (also known as ipamorelin acetate in some research contexts) is a synthetic pentapeptide that acts as a growth hormone secretagogue (GHS) and ghrelin receptor agonist. It belongs to the class of growth hormone-releasing peptide (GHRP) mimetics. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular formula of C38H49N9O5 and a molecular weight of approximately 711.85 g/mol. Sermorelin (also known as GRF 1-29 or sermorelin acetate) is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It has a molecular formula of C149H246N44O42S and a molecular weight of approximately 3357.9 g/mol. Both compounds are studied for their effects on the growth hormone (GH)–insulin-like growth factor-1 (IGF-1) axis, but they act through distinct receptor families: ipamorelin targets the growth hormone secretagogue receptor 1a (GHSR-1a), while sermorelin targets the GHRH receptor.
The published research on these two compounds spans different experimental models and clinical contexts, from post-operative recovery to performance-enhancing peptide use. This comparison summarizes what the evidence shows for each, where the data are stronger, and what remains unmeasured.
Research Studies
Ipamorelin and post-operative gastrointestinal function
Two registered clinical trials have evaluated ipamorelin for post-operative recovery of gastrointestinal function. One study, NCT01280344, was designed to test whether post-operative administration of ipamorelin reduces time to recovery of gastrointestinal function in patients who have undergone partial small and/or large bowel resection [1]. A separate trial, NCT00672074, aimed to determine if ipamorelin is safe and effective in the management of post-operative ileus [2]. These studies focus on a specific clinical endpoint—recovery of bowel function after surgery—rather than on performance or body composition. The results of these trials are not summarized in the available evidence block, so the outcomes remain to be reported.
Sermorelin and the GH-IGF-1 axis in clinical and self-administration contexts
Sermorelin is classified as a GHRH analogue, a class that also includes tesamorelin and CJC-1295 with or without DAC [4]. The published literature describes sermorelin as one of the agents commonly encountered in clinical practice and in online self-administration protocols intended to modulate the GH-IGF-1 axis [4]. However, the evidence block does not provide specific clinical trial results for sermorelin itself; the available data describe its classification and its presence in the broader landscape of performance-enhancing peptides.
Ipamorelin and the GH-IGF-1 axis in self-administration contexts
Ipamorelin is listed among growth hormone secretagogues (GHS) that are marketed as "research compounds" and used in self-administration protocols to modulate the GH-IGF-1 axis [4]. The same source groups ipamorelin with other GHS such as GHRP-2, GHRP-6, and hexarelin [4]. This indicates that ipamorelin is recognized in the literature as a member of this class, but the evidence block does not provide specific outcome data from controlled trials of ipamorelin for performance or body composition endpoints.
Ipamorelin and cisplatin-induced weight loss in ferrets
A study in ferrets investigated whether ghrelin mimetics, including ipamorelin, can alleviate weight loss and inhibition of feeding during acute and delayed phases of cisplatin-induced emesis [9]. The study reported that ipamorelin inhibited cisplatin-induced weight loss in this animal model [9]. This finding is specific to the ferret model and the cisplatin-induced emesis context; it does not establish effects in humans or in other conditions.
Ipamorelin and the hypothalamic-pituitary-testicular axis in cichlid fish
Research on the cichlid fish Oreochromis mossambicus examined the impact of ipamorelin acetate on the reproductive axis [10]. The study was designed to test the role of ghrelin agonists in controlling physiological systems in fish [10]. This work is limited to the fish model and does not provide data on mammalian or human reproductive function.
Sermorelin and musculoskeletal injury or athletic performance
Several reviews have examined peptide therapies for musculoskeletal injuries and athletic performance, including sermorelin as a GHRH analogue [7][11][12]. These sources describe the pharmacological mechanisms and regulatory status of approved and unapproved peptides but do not report specific efficacy outcomes for sermorelin in these contexts [7][11][12]. The evidence block does not contain controlled trial results for sermorelin in musculoskeletal recovery or performance enhancement.
Ipamorelin and musculoskeletal injury or athletic performance
Ipamorelin is also mentioned in reviews of peptides used in sports medicine and performance enhancement [7][11][12]. As with sermorelin, these reviews discuss the mechanisms and the gray market context but do not provide specific efficacy data for ipamorelin in musculoskeletal injury or athletic performance [7][11][12]. The evidence block does not include controlled trials of ipamorelin for these endpoints.
Purity and quality of research-grade peptides
A study evaluating research-grade peptides marketed directly to consumers found extensive variability in purity and measured abundance [5]. The study analyzed a large independent testing dataset and compared the cost of these peptides to compounded and FDA-approved alternatives [5]. This finding applies to the broader market of gray market peptides and is not specific to ipamorelin or sermorelin, but it is relevant to any research involving these compounds obtained from such sources.
Safety and regulatory context for peptide therapies
Reviews of peptide therapeutics in gerontology and sports medicine highlight that clinical adoption has outpaced high-quality evidence and regulatory consensus for many compounds [6][12]. The evidence block notes that peptides are a rapidly expanding drug class with a parallel unregulated gray market [5]. For both ipamorelin and sermorelin, the regulatory status and safety profiles are discussed in the context of approved and unapproved peptides [7][12]. However, the evidence block does not provide specific safety data from controlled trials for either compound beyond the registered clinical trials for ipamorelin in post-operative settings [1][2].
Comparative summary of evidence
The table below summarizes the types of evidence available for each compound based on the provided sources.
| Compound | Class | Receptor target | Clinical trial evidence | Animal model evidence | Review mentions |
|---|---|---|---|---|---|
| Ipamorelin | GHS / ghrelin agonist | GHSR-1a | Post-operative GI function and ileus (NCT01280344, NCT00672074) [1][2] | Cisplatin-induced weight loss in ferrets [9]; reproductive axis in cichlid fish [10] | Performance-enhancing peptides [4]; sports medicine [7][11][12] |
| Sermorelin | GHRH analogue | GHRH receptor | None specified in evidence block | None specified in evidence block | Performance-enhancing peptides [4]; sports medicine [7][11][12]; gerontology [6] |
The evidence block does not contain head-to-head studies comparing ipamorelin and sermorelin. The clinical trial data for ipamorelin are limited to post-operative gastrointestinal endpoints [1][2], while sermorelin is discussed primarily in reviews of peptide classes and performance-enhancing agents [4][6][7]. Neither compound has published controlled trial results for musculoskeletal injury, body composition, or athletic performance in the provided evidence. The animal studies for ipamorelin are specific to ferrets and cichlid fish [9][10] and cannot be directly extrapolated to humans. The purity and quality issues identified in the gray market [5] apply to both compounds if obtained from such sources.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
- [2] Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
- [3] Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.
- [4] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- [5] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
- [6] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- [7] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- [8] Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
- [9] The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
- [10] The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
- [11] Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- [12] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.